研究発表等（講演・口頭発表等） - 佐治 重衡
-
大規模自然災害時のがん診療とがん患者さんへのケア
第18回日本臨床腫瘍学会学術集会(JSMO2021)
-
がんゲノム医療時代の進行再発乳がん治療とリムパーザの位置づけ
第18回日本臨床腫瘍学会学術集会(JSMO2021)
-
PD12-11(Spotlight Poster Discussion). Patient-reported outcomes from the Phase III IMpassion031 trial of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer.
San Antonio Breast Cancer Symposium 2020
-
GS3-04(GENERAL SESSION). Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) forPIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A.
San Antonio Breast Cancer Symposium 2020
-
GS3-02(GENERAL SESSION) . Patient-reported outcomes (PROs) from the Ph 3 IMpassion031 trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast cancer (eTNBC).
San Antonio Breast Cancer Symposium 2020
-
PD3-11(Spotlight Poster Discussion). A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study.
San Antonio Breast Cancer Symposium 2020
-
PS5-06 (Poster Session). Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial.
San Antonio Breast Cancer Symposium 2020
-
OT-30-01(Ongoing Trials Posters). KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).
San Antonio Breast Cancer Symposium 2020
-
PD1-09(Spotlight Poster Discussion). Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
San Antonio Breast Cancer Symposium 2020
-
3MO - IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC) (ID 512).
ESMO asia 2020.
-
68TiP: KEYLYNK-009:A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC. (ID 515)
ESMO asia 2020.
-
Invited Discussant abstracts 2MO, LBA1, 47MO and 48MO (ID 1072).
ESMO asia 2020.
-
乳癌診療の新たな構築2020、
第58回日本癌治療学会学術集会
-
ホルモン陽性HER2陽性進行再発乳癌におけるフルベストラントの治療成績（JBCRG-C06 Safari試験）の検討
第28回日本乳癌学会総会
-
CLDN4の乳癌悪性形質増強機構の解明
第28回日本乳癌学会総会
-
内分泌療法耐性乳癌細胞株の抗エストロゲン薬の感受性はPI3K経路阻害薬により回復できる
第28回日本乳癌学会総会
-
乳癌における術前抗がん剤治療後の病理学的形質転換症例の検討
第28回日本乳癌学会総会
-
大規模コホート研究からの閉経後ER陽性進行・再発乳癌におけるOSに関与する因子の検討（JBCRG-C06: Safari）
第28回日本乳癌学会総会
-
CDK4/6阻害薬を使用した進行再発乳癌30例の治療成績
第28回日本乳癌学会総会
-
術後内分泌療法がER+HER2-進行再発乳癌の内分泌療法に及ぼす影響:JBCRG-C06サブ解析
第28回日本乳癌学会総会